Amphastar Pharmaceuticals Cost of Revenue 2011-2025 | AMPH

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Amphastar Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
358 M	293 M	250 M	238 M	207 M	190 M	188 M	150 M	151 M	174 M	159 M	143 M	114 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
358 M	114 M	201 M

Quarterly Cost of Revenue Amphastar Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
93.2 M	87.9 M	85.3 M	-	89.3 M	87.2 M	81.7 M	-	72.2 M	73 M	66.2 M	-	61.6 M	60.1 M	64.5 M	-	61 M	54.3 M	58.1 M	-	46.9 M	52.6 M	47.9 M	-	44.9 M	46.7 M	48.9 M	-	46.3 M	45 M	41.4 M	-	37.4 M	38.4 M	33.8 M	-	36.6 M	36.3 M	34.5 M	-	46.3 M	40.5 M	43.6 M	-	47.9 M	34 M	33.4 M	-	39 M	35 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
93.2 M	33.4 M	54 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
AbbVie ABBV	16.9 B	$ 223.01	-0.99 %	$ 395 B	USA
Aclaris Therapeutics ACRS	2.79 M	$ 3.38	3.21 %	$ 261 M	USA
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
Ascendis Pharma A/S ASND	3.52 M	$ 212.3	5.5 %	$ 5 B	Danmark
BioVie BIVI	312 K	$ 1.54	-2.53 %	$ 2.28 M	USA
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Aptorum Group Limited APM	421 K	$ 1.33	-1.48 %	$ 7.25 M	China
AstraZeneca PLC AZN	12.4 B	$ 90.34	-1.28 %	$ 96.9 B	Britain
Anika Therapeutics ANIK	63.6 M	$ 9.53	-1.19 %	$ 140 M	USA
Aytu BioScience AYTU	20.6 M	$ 2.33	2.3 %	$ 14.6 M	USA
Axon Enterprise AXON	841 M	$ 586.28	3.15 %	$ 44.4 B	USA
Biogen BIIB	2.31 B	$ 173.03	-2.55 %	$ 25.2 B	USA
BioNTech SE BNTX	2.91 B	$ 95.9	0.17 %	$ 27.2 B	Germany
Biohaven Pharmaceutical Holding Company Ltd. BHVN	91.7 M	$ 11.55	8.86 %	$ 747 M	USA
Catalyst Biosciences CBIO	4.64 M	$ 15.32	5.73 %	$ 1.01 B	USA
BeiGene, Ltd. BGNE	70.7 M	-	0.49 %	$ 251 B	Cayman-islands
Cerus Corporation CERS	33.4 M	$ 2.14	13.23 %	$ 395 M	USA
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
Berkeley Lights BLI	24.8 M	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	33.5 M	-	-	$ 546 M	USA
Bristol-Myers Squibb Company BMY	14 B	$ 51.05	-0.32 %	$ 103 B	USA
ADiTx Therapeutics ADTX	627 K	$ 2.36	-7.29 %	$ 31.1 K	USA
BioXcel Therapeutics BTAI	2.14 M	$ 2.1	-4.34 %	$ 5.32 M	USA
Coherus BioSciences CHRS	159 M	$ 1.42	6.77 %	$ 134 M	USA
Celldex Therapeutics CLDX	200 K	$ 28.33	0.5 %	$ 1.82 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Baudax Bio BXRX	7.01 M	-	0.59 %	$ 63 K	USA